{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:30:10Z","timestamp":1787016610110,"version":"build-2736575974"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Scynexis, Inc."},{"name":"Save Our Sick Kids Foundation"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,5,21]]},"abstract":"<jats:p>\n                    Ibrexafungerp (formerly SCY-078) is a semisynthetic triterpenoid and potent (1\u21923)-\u03b2-\n                    <jats:sc>d<\/jats:sc>\n                    -glucan synthase inhibitor. We investigated the\n                    <jats:italic>in vitro<\/jats:italic>\n                    activity, pharmacokinetics, and\n                    <jats:italic>in vivo<\/jats:italic>\n                    efficacy of ibrexafungerp (SCY) alone and in combination with antimold triazole isavuconazole (ISA) against invasive pulmonary aspergillosis (IPA). The combination of ibrexafungerp and isavuconazole in\n                    <jats:italic>in vitro<\/jats:italic>\n                    studies resulted in additive and synergistic interactions against\n                    <jats:italic>Aspergillus<\/jats:italic>\n                    spp.\n                  <\/jats:p>","DOI":"10.1128\/aac.02429-19","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T06:11:01Z","timestamp":1583993461000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":48,"title":["Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1\u21923)-\u03b2-\n                    <scp>d<\/scp>\n                    -Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis"],"prefix":"10.1128","volume":"64","author":[{"given":"Vidmantas","family":"Petraitis","sequence":"first","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruta","family":"Petraitiene","sequence":"additional","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aspasia","family":"Katragkou","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Disease Department, Nationwide Children\u2019s Hospital, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Bo Win","family":"Maung","sequence":"additional","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Naing","sequence":"additional","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Povilas","family":"Kavaliauskas","sequence":"additional","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Barat","sequence":"additional","affiliation":[{"name":"Scynexis, Inc., Jersey City, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katyna","family":"Borroto-Esoda","sequence":"additional","affiliation":[{"name":"Scynexis, Inc., Jersey City, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nkechi","family":"Azie","sequence":"additional","affiliation":[{"name":"Scynexis, Inc., Jersey City, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Angulo","sequence":"additional","affiliation":[{"name":"Scynexis, Inc., Jersey City, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Walsh","sequence":"additional","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA"},{"name":"Department of Pediatrics, Weill Cornell Medicine, New York, New York, USA"},{"name":"Department of Microbiology and Immunology, Weill Cornell Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/651263"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-206291"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/13693780902718339"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181acd956"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2009.03.008"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01510-19"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1536546"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02145-13"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00161-17"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01102-17"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx033"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00244-18"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01588-12"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks466"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04445-14"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx422"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02068-16"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00585-18"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix198"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12769"},{"key":"e_1_3_3_22_2","volume-title":"ASM Microbe 2018","author":"Petraitis V","year":"2018","unstructured":"Petraitis V, Kavaliauskas P, Planciuniene R, Virgailis M, Petraitiene R, Barat S, Borroto-Esoda K, Angulo D, Walsh TJ. 2018. In vitro activity of SCY-078 in combination with isavuconazole or amphotericin B against medically important moulds, abstr 498. ASM Microbe 2018. ASM, Atlanta, GA."},{"key":"e_1_3_3_23_2","unstructured":"Scynexis Inc. 2019. Study to evaluate the safety and efficacy of the combination therapy of ibrexafungerp (SCY-078) with voriconazole in patients with invasive pulmonary aspergillosis (SCYNERGIA). ClinicalTrials registration no. NCT03672292. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03672292."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/375420"},{"key":"e_1_3_3_25_2","volume-title":"CLSI document M38-A2","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved Standard\u20142nd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03261-14"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.47.1.106-117.2003"},{"key":"e_1_3_3_28_2","volume-title":"Guide for the care and use of laboratory animals","author":"National Research Council","year":"2011","unstructured":"National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.","edition":"8"},{"key":"e_1_3_3_29_2","first-page":"467","article-title":"Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits","volume":"38","author":"Walsh TJ","year":"1988","unstructured":"Walsh TJ, Bacher J, Pizzo PA. 1988. Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. Lab Anim Sci 38:467\u2013471.","journal-title":"Lab Anim Sci"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.857-869.2001"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.60.6.2237-2245.1992"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00674-08"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02429-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02429-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:45:40Z","timestamp":1645461940000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02429-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,21]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,5,21]]}},"alternative-id":["10.1128\/AAC.02429-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.02429-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,21]]},"assertion":[{"value":"2019-12-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02429-19"}}